Apollo Endosurgery to Report Second Quarter Financial Results on August 3, 2021
Apollo Endosurgery, a leader in minimally invasive medical devices, will release its Q2 2021 financial results on August 3, 2021, after market close. A conference call is scheduled at 3:30 p.m. CT to discuss the results. The company focuses on innovative solutions for gastrointestinal conditions, with products available in over 75 countries. Apollo emphasizes the importance of their device-based therapies in reducing healthcare costs and complication rates.
- Strong global presence with products in over 75 countries.
- Focus on innovative, less invasive medical devices may enhance market competitiveness.
- Risks associated with COVID-19 impacting operations and product demand.
- Potential adverse events related to products could affect market perception.
- Dependence on regulatory approvals which may delay product adoption.
AUSTIN, TX / ACCESSWIRE / July 27, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the second quarter ended June 30, 2021 on Tuesday, August 3, 2021 after the market closes. In conjunction with the release, Apollo will host a conference call at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. To join the call by telephone, please dial +1-973-528-0011. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.apolloendo.com.
A replay of the webcast will be made available on Apollo's website, www.apolloendo.com, shortly after completion of the call.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on the development of next-generation, less invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, management of gastrointestinal complications and the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo's common stock is traded on NASDAQ Global Market under the symbol "APEN". For more information on Apollo Endosurgery visit www.apolloendo.com.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. In addition, there is uncertainty about the continued spread of the COVID-19 virus and the impact it may have on the Company's operations, the demand for the Company's products, the Company's liquidity position, global supply chains and economic activity in general. Important factors that could cause actual results to differ materially include: reports of adverse events related to our products, outcomes of clinical studies related to our products, development of competitive products or procedures, regulatory approvals and extensive regulatory oversight by the FDA or other regulatory authorities, unfavorable media coverage related to our products or related procedures, coverage and reimbursement decisions by private or government payors, Apollo's ability to support the adoption of its products and broaden its product portfolio; the potential size of Apollo's addressable markets; the execution of our gross margin improvement projects; the availability of cash for Apollo's future operations as well as other factors detailed in Apollo's periodic reports filed with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2020 and its Form 10-Q for the period ending March 31, 2021. Copies of reports filed with the SEC are posted on Apollo's website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
Disclosure Information
Apollo uses the investor relations section of its website as a means of complying with its disclosure obligations under Regulation FD. Accordingly, we recommend that investors should monitor Apollo's investor relations website in addition to following Apollo's press releases, SEC filings, and public conference calls and webcasts.
Contact:
Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com
SOURCE: Apollo Endosurgery, Inc.
View source version on accesswire.com:
https://www.accesswire.com/657112/Apollo-Endosurgery-to-Report-Second-Quarter-Financial-Results-on-August-3-2021
FAQ
When will Apollo Endosurgery announce its second quarter financial results?
What time is the conference call for Apollo's financial results?
What are the primary products offered by Apollo Endosurgery?
What is the stock symbol for Apollo Endosurgery?
What challenges does Apollo Endosurgery face?
